Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 227 followers
Latest posts
Last updated 4 days ago
Lilly confirms date and conference call for third-quarter 2024 financial results announcement
4 days ago
INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
4 days ago
Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's...
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
6 days ago
Data show more patients treated with mirikizumab achieved histologic response at Week...
Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer
12 days ago
INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced...
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
18 days ago
Indiana facility will combine research, manufacturing and the latest technology to innovate...
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
25 days ago
Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
26 days ago
Japan is the second major market where Kisunla has received approval Kisunla...
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
about 1 month ago
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that...
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
about 1 month ago
Company ups manufacturing investment in Limerick by $1 billion ; unveils new...
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
about 1 month ago
Detailed results were published in The Lancet and simultaneously presented at the...
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
about 1 month ago
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and...
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
about 1 month ago
INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...